Skip to main content
Rakovina Therapeutics Inc. logo

Rakovina Therapeutics Inc. — Investor Relations & Filings

Ticker · RKV ISIN · CA75103L1013 LEI · 254900O0YVEUNI9UM016 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 191 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country CA Canada
Listing TSXV RKV

About Rakovina Therapeutics Inc.

https://www.rakovinatherapeutics.com/

Rakovina Therapeutics Inc. is a biopharmaceutical research company focused on the development of innovative, targeted cancer treatments. The company's therapeutic approach centers on novel small-molecule compounds designed to modulate the DNA-damage response (DDR) pathway. Rakovina leverages artificial intelligence (AI) in its drug discovery programs to accelerate the identification and synthesis of new compounds, aiming to improve patient outcomes.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a formal notice of the upcoming Annual General Meeting and record dates filed via SEDAR+ as a regulatory announcement. It does not contain the full proxy materials or information statement itself, nor the AGM presentation or voting results. It serves to inform regulators (and indirectly investors) of meeting logistics. This aligns with a general regulatory filing announcement rather than the actual report or detailed materials, making RNS the appropriate fallback category.
2026-04-24 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the presentation of preclinical data at the AACR 2026 Annual Meeting. It contains scientific program details, collaboration descriptions, and forward‐looking statements, but includes no financial results, no formal regulatory form references, no shareholder votes, or management changes. It is not an earnings release, investor presentation deck, or detailed financial report. Therefore, it does not match any specific category and is best classified under the fallback category “Regulatory Filings” (RNS).
2026-04-22 English
News release - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of General Meeting' for Paladin Energy Ltd. It contains the agenda, proposed resolutions (election of directors, approval of performance rights), voting prohibitions, and voting exclusions. This document is sent to shareholders to provide information and request their votes for an upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2026-02-04 English
News release - English.pdf
M&A Activity Classification · 1% confidence The document is a press release announcing an amended arrangement agreement for a privatization transaction (takeover/merger). It details the terms of the acquisition, the support of a major shareholder, and the upcoming special meeting of shareholders. This falls under M&A activity (takeover bids/mergers).
2026-02-04 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a 'Material Change Report' (Form 51-102F3) filed under Canadian securities regulations. It details multiple significant corporate events: a private placement of shares and debentures (financing), a debt restructuring, and changes to the board of directors and management. While it touches on management changes (MANG) and financing (CAP), the 'Material Change Report' is a formal regulatory filing required by Canadian securities law to disclose any event that would reasonably be expected to have a significant effect on the market price or value of the securities. Since it covers multiple categories and is a formal regulatory disclosure document, 'RNS' (Regulatory Filings) is the most appropriate classification.
2026-02-03 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release from Rakovina Therapeutics Inc. that covers multiple topics: a capital/financing update (convertible debenture extension, debt restructuring, and private placements) and board/management changes (new CEO, new board members, and resignations). While it contains management information, the primary driver of the announcement is the significant capital and financing activity. According to the filing definitions, 'CAP' (Capital/Financing Update) is the most appropriate classification for documents detailing fundraising and debt restructuring, which are the core subjects of this release.
2026-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.